Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Sarepta Therapeutics Stock Soars Despite Adverse Event Worries

TheMotleyFool 
0 0 02.10.17
Sarepta Therapeutics Stock Soars Despite Adverse Event Worries
 
Sarepta Therapeutics Stock Soars Despite Adverse Event Worries

Late last week, some Sarepta Therapeutics (NASDAQ: SRPT) investors were worried. Now the weekend is over, and all of those worries seem to have dissipated.

Concerns arose after the U.S. Food and Drug Administration (FDA) made its database of prescription drug adverse events easily searchable. Sarepta stock fell on Friday after investors saw troubling adverse event data for the biotech's Duchenne muscular dystrophy (DMD) drug Exondys 51. However, Sarepta's share price jumped 7% on Monday. What happened to ease investors' minds?

Image source: Getty Images.

Continue reading


Source: Fool.com

Sarepta Therapeutics Stock

€136.05
1.930%
There is an upward development for Sarepta Therapeutics compared to yesterday, with an increase of €2.60 (1.930%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Sarepta Therapeutics stock is not clear.
However, we have a potential of -4.45% for Sarepta Therapeutics as the target price of 130 € is below the current price of 136.05 €.
Show more
Like: 0
SRPT
Share

Comments

Not a member yet? Sign up for free!